Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
El Mundo on MSN17h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...
Gilead Sciences (GILD) ended the recent trading session at $91.86, demonstrating a -0.57% swing from the preceding day's closing price. On the other hand, the Dow registered a loss of 0.2%, and the ...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback